Previous close | 78.75 |
Open | 81.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 77.22 - 81.00 |
52-week range | 55.64 - 98.17 |
Volume | |
Avg. volume | 562 |
Market cap | 25.695M |
Beta (5Y monthly) | 1.16 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.72 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
In this article, we will be taking a look at the 30 countries with the lowest depression rates. If you do not want to learn about the global depression treatment market, head straight to the 5 Countries with the Lowest Depression Rates. In countries with the lowest depression rates, individuals experience lower prevalence rates of […]
In this article, we will take a look at the top 20 cloudiest cities in the U.S., Ranked. If you would like to skip our discussion on the diverse weather patterns across the country, you can go to the 5 Cloudiest Cities in the U.S., Ranked. Ranking fourth in terms of land area globally, the […]
77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by the Epworth Sleepiness Scale (ESS), despite being treated 74% of treated narcolepsy type 1 patients exhibit cognitive impairment, as assessed by the British Columbia Cognitive Complaints Inventory (BC-CCI) Depression and anxiety were experienced by 45% and 57% of narcolepsy type 1 patients, respectiv